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Orthotopic mouse modelOsteosarcoma (OS) is the most common primary bone malignancy in children and adolescents. More than 30% of
patients develop lung metastasis, which is the leading cause of mortality. Recently, the extracellular matrix protein
Cyr61 has been recognized as a malignancy promoting protein in OS mouse model with prognostic potential in
human OS. In this study, we aimed at the identiﬁcation of novel Cyr61-interacting proteins.
Here we report that Cyr61 associates with Caprin-1, and confocal microscopy showed that stable ectopic expres-
sion of Caprin-1 leads to the formation of stress granules containing Caprin-1 and Cyr61, confers resistance to
cisplatin-induced apoptosis, and resulted in constitutive phosphorylation of Akt and ERK1/2. Importantly, ectopic
expression of Caprin-1 dramatically enhanced primary tumor growth, remarkably increased lung metastatic load
in a SCID intratibial OS mouse model, and decreased signiﬁcantly (p b 0.0018) the survival of the mice. Although
Caprin-1 expression, evaluated with a tissue microarray including samples from 59 OS patients, failed to be an
independent predictor for the patients' outcome in this limited cohort of patients, increased Caprin-1 expression
indicated a tendency to shortened overall survival, and more strikingly, Cyr61/Caprin-1 co-expression was
associated with worse survival than that observed for patients with tumors expressing either Cyr61 or Caprin-1
alone or none of these proteins. The ﬁndings imply that Caprin-1 may have a metastasis promoting role in OS
and show that through resistance to apoptosis and via the activation of Akt and ERK1/2 pathways, Caprin-1 is
signiﬁcantly involved in the development of OS metastasis.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Osteosarcoma (OS) is the most common highly malignant primary
bone tumor of children and young adults [1]. OS has a high propensity
for lung metastasis which is the main cause of death of OS patients
[2,3]. The cellular and molecular events that initiate and propagate
osteosarcomagenesis remain poorly understood [4,5]. Thus, a more de-
tailed understanding of the molecular pathophysiological mechanisms
causing OS and metastasis is required for the development of more
effective therapeutics and/or a more personalized therapy. Recently,
our group and others found that the expression of Cyr61 in primary
tumor tissue correlated with poor prognosis for the OS patients and
that overexpression of Cyr61 in experimental OS in mice enhanced
lung metastasis [6,7]. Cyr61, a member of the CCN (CYR61/CTGF/
NOV) family, is a multifunctional matricellular protein with regulatory
functions in several processes involved in tumor biology, and for which
aberrant expression was associated with a myriad of pathologies,Research, Balgrist University
+41 44 386 1669.
bile).
rights reserved.including various cancers [8–12]. Cyr61 can either associate with the
extracellular matrix and cell surfaces or localizes in the cytoplasm
and nucleus [13].
In the present study, we aimed at the identiﬁcation of novel Cyr61-
interacting proteins. By combined Cyr61 immunoprecipitation andmass-
spectrometric analysis, we identiﬁed Caprin-1 (cytoplasmic activation/
proliferation-associated protein1) as a novel Cyr61-interacting protein.
Caprin-1 is a member of a family of cytoplasmic proteins that is highly
conserved in vertebrates and that tightly correlates with cell proliferation
[14], and is required for normal progression through theG1-S phase of the
cell cycle [15,16]. The amino acid sequence of Caprin-1, consisting of 709
amino acids, contains an RGG motif characteristic for RNA-binding
proteins [14]. Indeed, Caprin-1 was found to accumulate in the leading
edge of migrating cells and was shown to co-localize with the GTPase-
activating protein Src homology 3 domain binding protein (G3BP-1) in
cytoplasmic RNA granules associatedwithmicrotubules [17,18]. Interest-
ingly, Caprin-1 associates with another form of RNA granule in cell lines,
cytoplasmic stress granules (SG) which are cytoplasmic aggregates that
regulate the translation of subsets of mRNA following exposure to envi-
ronmental stress. Caprin-1 has been shown to be a component of the
SG in HeLa cells and ectopic expression of Caprin-1 protein alone is
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translation initiation factor 2α (eIF-2α) through Caprin-1's ability to
bind mRNAs [17]. On the other hand, the expression of Caprin-1 was
shown to be suppressed by either overexpression of wild-type p53
(wt-p53) [19] or by interaction of miR-16 with the 3′ UTR of Caprin-1
mRNA [20].
In this study, we identiﬁed Caprin-1 as a novel Cyr61-interacting
protein. We report that stable ectopic expression of Caprin-1 provoked
co-accumulation with Cyr61 in SG, structures known to be involved in
apoptosis protective processes. We further show that forced expression
of Caprin-1 confers to the cells a more resistant phenotype to cisplatin-
induced apoptosis, and leads to a constitutive activation of the Akt
and ERK1/2 signaling pathways. Importantly, ectopic expression of
Caprin-1 enhanced primary tumor growth, remarkably increased lung
metastatic load in an intratibial OS model in SCID mice, and decreased
signiﬁcantly the survival of the mice. Our ﬁndings suggest that
Caprin-1 may function as a tumor promoter in OS metastasis and eluci-
date a novel role of Caprin-1 in OS pathogenesis and metastasis.
2. Materials and methods
2.1. Cell culture and transfection
Human SaOS-2 (HTB-85) and U2OS OS cells were cultured as previ-
ously described [7]. SaOS-2 and U2OS cells stably overexpressing
Caprin-1 with an N-terminal Flag-tag (SaOS-2/Caprin-1 and U2OS/
Caprin-1) were obtained by calcium phosphate precipitation-mediated
transfection [21] with the plasmid pCMV-Tag4-Flag-Caprin-1 and
subsequent selection for neomycin resistance with 500 μg/ml G418
(Invitrogen, Carlsbad, CA, USA). Control SaOS-2 or U2OS cells trans-
fected with the pCMV-Tag4 empty vector (SaSO-2/EV or U2OS/EV
cells) were obtained accordingly.
2.2. Puriﬁcation of Cyr61-interacting proteins and mass spectrometry
For the identiﬁcation of Cyr61-interacting proteins, lysates of
SaOS-2 OS cells were prepared as described previously [7]. Superna-
tants were collected and incubated at 4 °C overnight with Cyr61 anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The
immunocomplexes were adsorbed to protein A/G Plus-Agarose
beads (Santa Cruz Biotechnology, Santa Cruz, CA, USA). The beads
were washed 4 times with lysis buffer before the proteins were eluted
with Laemmli buffer and separated by 6%–15% gradient sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The
gels were stained with Coomassie (Coomassie G250, BioRad Labora-
tories, Hercules, CA, USA), selected protein bands were excised and
digested with trypsin. The generated peptides were analyzed by
nanoLC–MS/MS on a LCQ Deca XP (Thermo Scientiﬁc) and identiﬁed
with MASCOT (Matrix Science) searching the data base UniProtKB/
Swiss-Prot 2011_08.
2.3. Generation of Caprin-1 antibodies
The peptide NH2-CSHATEQRPQKEPID-CONH2 corresponding to
amino acid sequence 452 to 465 of human Caprin-1, was chemically
cross-linked to keyhole limpet hemocyanin (KLH). The conjugation
product was used by Pineda Antikörper-Service (Berlin, Germany)
for the immunization of three rabbits. Caprin-1 afﬁnity-puriﬁed anti-
bodies obtained from Pineda Antikörper-Service were screened by
Western blot analysis of extracts of SaOS-2 and of SaOS-2/Caprin-1
cells.
2.4. Immunocytochemistry and confocal laser microscopy
Cells grown on glass coverslips were ﬁxed with 3.7% formaldehyde
in phosphate-buffered saline (PBS) for 15 min and permeabilized with0.2% Triton X-100. The ﬁxed cells were treated with blocking solution
(2% fetal bovine serum in PBS) and stained with mouse anti-Cyr61
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-Caprin-1,
or goat anti-TIA1 (Santa Cruz) in blocking solution (1:400) at room
temperature for 1 h. Cells were washed 3 times with PBS, and
stained with FITC-labeled donkey anti-mouse, Dylight 594-labeled
donkey anti-rabbit, or Cy5-labeled donkey anti-goat secondary anti-
bodies (Jackson ImmunoResearch Laboratories, Inc., Baltimore, Pike
West Grove, USA) at room temperature for 1 h. Nuclear DNA was
stainedwith 0.2 μg/ml 4′,6′-diaminidino-2-phenylindole (DAPI, Molec-
ular Probes Inc., Eugene, USA). Fluorescence imaging was performed
with a confocal laser scanning microscope (SP5, Leica, Heerbrugg,
Switzerland) equipped with a Plan-Apochromat 63 × NA 1.4 oil im-
mersion objective.
2.5. Immunoprecipitation and immunoblotting
Proteins were extracted from cultured cell lines and immu-
noblotted as described previously [7]. For immunoprecipitation,
500 μg of lysate in lysis buffer was pre-cleared by incubation with
50 μl of protein A/G Plus-Agarose beads (Santa Cruz) at 4 °C for 1 h
and centrifugation at 5000 g for 2 min. 10 μg of Caprin-1 or Cyr61
antibodies or of control immunoglobulin G (IgG) was then added to
the supernatants and the samples agitated at 4 °C overnight. Subse-
quently, 50 μl of protein A/G Plus-Agarose beads was added and the
samples incubated at 4 °C for 90 min. After centrifugation at 5000 g
for 2 min, pelleted beads were washed 4 times with lysis buffer and
bound proteins were eluted by boiling in Laemmli buffer and
subjected to SDS-PAGE. Proteins in immunoprecipitation, signaling
and apoptosis experiments were then analyzed with antibodies
to human Caprin-1, Cyr61 and GAPDH (Santa Cruz), Flag (Sigma,
Buchs, Switzerland), phospho-Akt, Akt, phospho-ERK1/2 and ERK1/
2, caspase 3, and PARP (Cell Signaling Technology, Danvers, MA,
USA). The apoptosis-provoking chemotherapeutic drug cisplatin was
purchased from Sigma.
2.6. Intratibial human OS xenograft model in SCID mice
The mice were housed and the tumor cells inoculated as reported
and in accordance with the guidelines of the “Schweizer Bundesamt
für Veterinärwesen” and of the local authorities [7]. Brieﬂy, 5 × 105
SaOS-2/EV or SaOS-2/Caprin-1 cells in 10 μl PBS were injected
intramedullary into the left tibia of individual mice under X-ray control
with a MX-20 DC Digital Radiography System (Faxitron X-ray Corpora-
tion, Lincolnshire, IL, USA). The health status of the mice was monitored
three times a week and primary tumor growth examined in 2-week in-
tervals by X-ray and by calculating the tumor volume from themeasure-
ments of the legs with a caliper. The equation length × (width)2 / 2 of
the tumor bearing tibia minus length × (width)2 / 2 of the control
tibia was used.
2.7. Histology of lung metastases
On the day of sacriﬁce, the lungs of themice were prepared, ﬁxed and
embedded into parafﬁn as described [7]. Ten 5 μm sections were collect-
ed at 200 μm intervals from each lung and mounted on SuperFrost®Plus
slides (Menzel GmbH & Co KG, Braunschweig, Germany) and then
processed for hematoxylin–eosin (HE) staining according to standard
protocols. The total area of all metastatic lesions recognized on an indi-
vidual section was determined with a MATLAB (v2009b, Mathworks,
MA) custommade program. Images were ﬁrst converted into binary im-
ages. Total lung tissue area was determined with a morphological close
operation to remove small gaps in between tissue and highlighted in
red. Metastatic lesions (target area)were identiﬁedwith amorphological
open operation to remove the areas of normal lung tissue and were
highlighted in green. To assess the proliferation index in vivo, we used
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marker of proliferation. Ki67 was immunostained with rabbit polyclonal
Ki67 antibody (Abcam, Cambridge, UK), and the immunostaining was
visualized with peroxidase-conjugated secondary antibodies (Vector
Laboratories Inc., Burlingeme, CA, USA), Vectastain® Elite ABC and a
substrate-chromogen system (Dako, Baar, Switzerland).2.8. Human OS tissue microarray, Caprin-1 immunostaining and
Kaplan–Meier analysis
Primary osteosarcoma biopsies of 59 patients and normal bone tis-
sue specimens were collected between June 1990 and December
2005 according to the regulations of the Swiss ethics committee. Clin-
ical information on the patients included is summarized in Table 1.
The tissue microarray (TMA) was arranged and 4.5 μm tissue sections
were processed as previously described [7,22], stained with Caprin-1
or Cyr61 antibodies (1:400) and counterstained with hematoxylin.
The grading of the TMA was performed based on both, the intensity
and the percentage of stained area. The intensity of the staining was
evaluated by eye by two independent investigators and the percent-
age of stained areas was calculated with a custom MATLAB program.
Immunostained (brown) and non-stained (blue) areas were deter-
mined by color deconvolution [23]. The percentage of Caprin-1 or
Cyr61 expressing tissue area was deﬁned as brown area (number of
brown pixels) divided by the total tissue area (number of blue and
brown pixels) × 100. Kaplan–Meier analysis was used to correlate
Caprin-1 or/and Cyr61 expression with the overall survival of the
patients.2.9. Statistical analysis
Results for the in vivo experiments are presented as mean ± stan-
dard error of the mean (SEM), and quantiﬁcation results of theWestern
blots are presented as the mean ± standard deviation (SD). Differences
between means were analyzed for signiﬁcance by unpaired t-test with
GraphPad Prism®5.01 software. The Kaplan–Meier analysis was statisti-
cally analyzedwith the log-rank test. p ≤ 0.05was considered statistical-
ly signiﬁcant.Table 1
Clinical characteristics of 59 patients included in OS TMA.
Patients (%)
Gender
Male 40 (68%)
Female 19 (32%)
Tumor type
Osteoblastic 39 (66%)
Chondroblastic 10 (17%)
Fibroblastic 6 (10%)
Telangiectatic 4 (7%)
Anatomic site
Extremities 49 (83%)
Axial (pelvis or spine) 10 (17%)
Metastasis
Total metastasis 22 (37%)
Present at diagnosis 5 (8%)
Metastasis after diagnosis 17 (29%)
Metastatic site
Lungs only 18 (82%)
Lungs/bones/other 4 (18%)3. Results
3.1. Identiﬁcation of Caprin-1 as a novel Cyr61-interacting protein
In search of novel Cyr61-interacting proteins, Cyr61 was immu-
noprecipitated from SaOS-2 OS cell extracts with afﬁnity puriﬁed
Cyr61 polyclonal antibodies. Subsequent mass spectrometric analysis
of co-precipitated proteins identiﬁed among others Caprin-1, a well
conserved cytoplasmic protein that is involved in the regulation of
cell proliferation (Fig. 1A). As described in the Materials and
methods section, we generated afﬁnity-puriﬁed Caprin-1 antibodies
in rabbits. On Western blots of proteins extracted from SaOS-2 and
SaOS-2/EV cells, Caprin-1 antibodies recognized a single prominent
protein with the expected molecular weight of 116 kDa (Fig. 1B,
lanes 1 and 3). The speciﬁcity of Caprin-1 antibodies was further con-
ﬁrmed by Western blot analysis of protein extracts of SaOS-2/
Caprin-1 cells overexpressing Flag-tagged Caprin-1. Caprin-1 anti-
bodies recognized Flag-tagged Caprin-1, also recognized by Flag anti-
bodies, and endogenous Caprin-1, which on 6% SDS-PAGE, migrated
slightly faster than Flag-tagged Caprin-1 and was also present in
extracts of control non-transfected SaOS-2 cells and in SaOS-2/EV
cells (Fig. 1B). The Caprin-1 antibodies were also suitable for immu-
nocytochemistry and localized endogenous Caprin-1 in the cytoplasm
of SaOS-2 cells as expected (Fig. 1C) [14,17].
3.2. Interaction and co-localization in stress granules of Caprin-1 and
Cyr61
The interaction of Caprin-1 and Cyr61 was further conﬁrmed by
co-immunoprecipitation of the two proteins in both directions using
SaOS-2 cell extracts. As shown before, immunoprecipitates obtained
with Cyr61 antibodies contained Cyr61 and Caprin-1, but, important-
ly, Caprin-1 antibodies precipitated Caprin-1 together with Cyr61
(Fig. 2A). In control precipitates of SaOS-2 cell extracts with rabbit
IgG, Caprin-1 and Cyr61 remained undetectable.
Consistent with a stable interaction between Caprin-1 and Cyr61 in
living cells, immunoﬂuorescent staining of the two proteins in SaOS-2/
Caprin-1 cells combined with confocal microscopy co-localized the two
proteins in cytoplasmic granule-like structures (Fig. 2B). Interestingly,
earlier studies in HeLa cells overexpressing Caprin-1 showed accumu-
lation of the protein in cytoplasmic stress granules (SG), characterized
by immunostaining with speciﬁc antibodies to the well-established SG
marker T-cell restricted antigen 1 (TIA1), which is normally localized in
the nucleus [17,24]. Therefore, we hypothesize that the cytoplasmic
granule-like structures in Fig. 2B might be SG. Interestingly, only cells
that highly expressed Caprin-1 showed stress granule formation and
are co-stained with TIA1 (Fig. 2C, arrow), whereas cells expressing
low levels of Caprin-1 showed uniform nuclear TIA1-staining with no
signs of stress granules (Fig. 2C, arrow head). These results indicate
that the overexpression of Caprin-1 in OS cells indeed provoked the
formation of stress granules. Furthermore, triple immunostaining
of Cyr61, Caprin-1 and TIA1 demonstrated Caprin-1 and Cyr61
co-localized within the SG (Fig. 2D). Taken together, this immunocyto-
chemical analysis demonstrated that the overexpression of Caprin-1
in SaOS-2 cells leads to the formation of SG and that the interaction
of overexpressed Caprin-1 with endogenous Cyr61 results in the
co-accumulation of the two proteins in SG.
3.3. Overexpression of Caprin-1 decreases the sensitivity of OS cells to
cisplatin-evoked apoptosis
SG are subcellular structures that are involved in cell death protec-
tive processes. Cisplatin is one of the most commonly used chemo-
therapeutic drugs for the treatment of OS. However, resistance to
cisplatin is a major cause of treatment failure in human OS [25].
Here, we investigated the postulated anti-apoptotic activity of
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Fig. 1. Identiﬁcation of Caprin-1 as a novel Cyr61-interacting protein. (A) SDS-PAGE of proteins immunoprecipitated from SaOS-2 cell extracts with control rabbit IgG (lane 1) or
rabbit antibodies to Cyr61 (lane 2). MW: molecular weight markers. Cyr61 (predicted size: 39 kDa) and co-precipitated Caprin-1 (predicted size: 116 kDa), identiﬁed by mass
spectrometry, were recognized in lane 2 and non-detectable control IgG (lane 1). (B) Validation of custom-made Caprin-1 afﬁnity-puriﬁed rabbit antibodies (Caprin-1 antibodies).
6% SDS-PAGE and Western blot analysis of whole-cell extracts of SaOS-2 (lane 1), of SaOS-2/Caprin-1 and of control SaSO-2/EV OS cells (lane 3) with Caprin-1 antibodies (top
panel) or with antibodies to Flag (middle panel) or to the protein loading control GAPDH (bottom panel), revealed indicated protein components of the predicted size. (C) Cytoplasmic
localization of Caprin-1 with Caprin-1 antibodies in SaOS-2 cells with DAPI-stained nuclei in blue (scale bar, 50 μm).
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EV and SaOS-2/Caprin-1 OS cells treated with increasing concentra-
tions of the drug (0, 0.7, 3.5, 7 μg/ml) for 48 h. As readouts of
cisplatin-evoked apoptosis, we examined on Western blots the cleav-
age of procaspase-3 and of PARP, a substrate of caspase-3, in the
extracts of non-treated and treated cells. Caspase-3 activation in
SaOS-2/EV cells treated with the indicated concentrations of cisplatin
resulted in a decrease in detectable levels of procaspase-3 (Fig. 3A). In
SaOS-2/Caprin-1 cells, however, procaspase-3 levels were indistin-
guishable from those in non-treated control cells (Fig. 3A). The cleav-
age of PARP in SaOS-2/EV cells in response to cisplatin treatment was
in perfect agreement with that observed for capsase-3 activation.
In SaOS-2/Caprin-1 cells, on the other hand, cisplatin-evoked PARP
cleavage was signiﬁcantly less compared to that observed in
SaOS-2/EV cells (Fig. 3B). Similarly, the treatment of U2OS/EV cells
with 3.5 μg/ml cisplatin resulted in a signiﬁcant cleavage of both
procaspase-3 and of PARP, whereas U2OS/Caprin-1, much like
SaOS-2/Caprin-1 cells, are more resistant to cisplatin (Fig. 3C and
D). Interestingly, pre-incubation of the cells with the pancaspase
inhibitor Z-VAD prior to cisplatin treatment signiﬁcantly inhibited
the decrease in procaspase-3 and PARP cleavage (Fig. 3C and D) dem-
onstrating that the observed cisplatin-evoked apoptosis in OS cells is
mainly caspase-dependent. Taken together, these results provide
solid evidence for an apoptosis-protective activity of overexpressed
Caprin-1 in two OS cell lines, SaOS-2 and U2OS.
3.4. Caprin-1 overexpression activates Akt and ERK1/2 in OS cells
Caprin-1 is involved in the regulation of cell proliferation [14,15].
The MAPK/ERK (mitogen-activated protein kinase/extracellular
signal-regulated kinase) and PI3K/Akt (lipid kinase phosphoinositide-
3-kinase) signaling pathways are well known to play an important
role in the transduction of signals to the cell nucleus, where they inﬂu-
ence the expression of genes that regulate important cellular processes
such as cell proliferation, apoptosis and survival. We therefore investi-
gated the status of the activation of Akt and ERK1/2 in two OS cell lines
SaOS-2 and U2OS. We found that overexpression of Caprin-1 in both
OS cell lines increases signiﬁcantly the levels of phosphorylated Akt
and ERK1/2 (Fig. 4). These in vitro results thus indicate that, inSaOS-2 and U2OS cells, Caprin-1 activates the Akt and ERK1/2 signaling
pathways and thereby suggests that Caprin-1 might have malignancy-
enhancing properties in OS.
3.5. Caprin-1 promotes intratibial primary tumor growth and lung
metastasis in mice
In order to investigate a potential malignancy promoting role of
Caprin-1 in OS, as suggested by its reported regulatory activities in
cell proliferation [14,15], and the constitutive activation of Akt and
ERK1/2 shown above, we compared the growth and metastasis of pri-
mary intratibial OS tumors derived from SaOS-2/Caprin-1 and
SaOS-2/EV cells in SCID mice. All mice injected with SaOS-2/
Caprin-1 cells developed primary tumors that became visible on
X-ray within 28 days after tumor cell injection (Fig. 5A, bottom
panels). In all mice injected with SaOS-2/EV control cells, on the
other hand, primary tumors remained radiologically undetectable
until day 64 after tumor cell injection (Fig. 5A, top panels), but all
these mice developed visible tumors between day 64 and day 90
post tumor cell inoculation. The tumors in all mice showed compara-
ble osteolytic and osteoblastic lesions in the bone and the surround-
ing soft tissue (Fig. 5A). A difference in volume between the
tumor-bearing and the control leg in mice injected with SaOS-2/
Caprin-1 cells was ﬁrst observed 21 days after the injection. In control
mice injected with SaOS-2/EV cells, measurable leg swelling was not
observed before day 64 after tumor cell inoculation. These ﬁndings
were consistent with the observed tumor progression monitored by
X-ray. It is important to note that the mice injected with SaOS-2/
Caprin-1 cells became moribund and had to be sacriﬁced before the
control mice even developed measurable or radiologically visible pri-
mary tumors (Fig. 5B). Accordingly, Kaplan–Meier survival curves
plotted for the mice in the two groups indicated a signiﬁcantly
(p b 0.0018) shorter mean survival of the SaOS-2/Caprin-1 cell
injected mice compared to SaOS-2/EV cell injected control animals
(Fig. 5C). Interestingly, at sacriﬁce the mean size of primary tumors
in the SaOS-2/Caprin-1 cell-injected mice was smaller to that in the
control animals, suggesting that the mice with SaOS-2/Caprin-1
cell-derived tumors suffered from severe metastasis. This was con-
ﬁrmed by histological examination of HE stained sections of the
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Fig. 2. Caprin-1 and Cyr61 co-immunoprecipitation and co-localization in stress granules of SaOS-2/Caprin-1 cells. (A) Co-immunoprecipitation of Cyr61 and Caprin-1 with anti-
bodies to Cyr61 or to Caprin-1 from extracts of SaOS-2 cells visualized on Western blots with antibodies to Caprin-1 (top panel) or to Cyr61 (bottom panel). Total cell extract
(lane 1), control immunoprecipitation (IP) with rabbit IgG (lane 2), or with Cyr61 (lane 3) or with Caprin-1 antibodies (lane 4). (B) Immunoﬂuorescent staining of Cyr61
(green), of Caprin-1 (red) and nuclear staining with DAPI (blue) in SaOS-2/Caprin-1 cells co-localized Caprin-1 and Cyr61 (yellow) in cytoplasmic granule-like structures, as
shown by confocal microscopy in overview images (top panels; scale bar, 20 μm) and in high magniﬁcation images of the boxed area (bottom panel; scale bar, 5 μm).
(C) SaOS-2/Caprin-1 cells with low levels of exogenous Caprin-1 (arrow heads), unlike cells with high levels of exogenous Caprin-1 (arrow), lacked stress granules as shown by
uniform cytoplasmic TIA1 immunostaining (red) visualized by confocal microscopy (scale bar, 10 μm). (D) Immunoﬂuorescent staining of Cyr61 (green) and Caprin-1 (red) in
stress granules identiﬁed by TIA1 (gray) and visualized by confocal microscopy in overview images (top panels; scale bar, 40 μm) and at high resolution of the boxed area (bottom
panels; scale bar 5 μm). Co-localization in the merged images on the far right in white.
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at least 60 days before the ﬁrst mouse in the control group had to be
sacriﬁced, they showed more and larger metastatic foci in their lungs
than the control mice (data not shown).
To conﬁrm this observation, we performed a second study, an
end-point study in which all mice of both SaOS-2/Caprin-1 and
control groups, were sacriﬁced on the same day, at the time when
the ﬁrst animals in the SaOS-2/Caprin-1 group became moribund. In
contrast to control mice with SaOS-2/EV cell-derived tumors, which
showed metastatic lung lesions less than 1 mm in diameter (Fig. 6A,
left panel), the mice with SaOS-2/Caprin-1 cell-derived tumors
presented large lung metastases (Fig. 6A, right panel) and, as a conse-
quence, the mean number of metastatic lesions per section was not
representative for the metastatic load. Consequently, the metastatic
load was deﬁned as the percentage of metastatic tissue per lung tis-
sue section estimated with a MATLAB program as described under
Materials and methods. In mice with SaOS-2/EV cell-derived tumors
the mean area of metastatic tissue amounted to approximately 5%
of the total area (Fig. 6A, a–b), whereas lung sections of SaOS-2/
Caprin-1 cell injected mice showed 44% metastatic tissue (Fig. 6A,
c–d).
Furthermore, we assessed the proliferation index by Ki67 immu-
nostaining of sections of primary tumors in mouse legs as well assections of the lungs. Ki67 staining of the primary tumors showed
no signiﬁcant difference in the percentage of proliferating cells in
vivo (Fig. 6B, upper panels). Similarly, Ki67 staining of the lung met-
astatic nodules showed no signiﬁcant difference in the percentage of
proliferating cells (Fig. 6B, lower panels). Interestingly, beside the
metastatic nodules, the healthy lung tissue of mice injected with
SaOS-2/Caprin-1 cells appears to contain signiﬁcantly more prolifera-
tive cells in comparison to the healthy lung tissue in control mice
(Fig. 6B, lower panels). Altogether, the results of these in vivo exper-
iments in mice conﬁrmed the postulated more malignant phenotype
of SaOS-2/Caprin-1 compared to SaOS-2/EV cells that consequently
accounted for the observed shorter survival of the SaOS-2/Caprin-1
compared to the control SaOS-2/EV tumor bearing mice.
3.6. Expression of Caprin-1 in human OS tissues
Based on our in vivo results, we hypothesized that the expression of
Caprin-1 in human OS primary tumors might affect the aggressiveness
of the disease and, consequently, the patient's survival. The expression
of Caprin-1 was therefore investigated immunohistochemically in OS
primary tumor tissue on a tissuemicroarray (TMA). Representative im-
munohistochemical staining is shown in Fig. 7A. A Kaplan–Meier sur-
vival analysis demonstrated that, irrespective of metastatic or local
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Fig. 3. Overexpression of Caprin-1 in OS cells inhibits apoptosis. (A) Representative Western blot analysis of procaspase-3 and PARP cleavage in SaOS-2/EV cells (lane 1) and in
SaOS-2/Caprin-1 cells (lane 2) in response to treatment for 48 h with indicated doses of cisplatin. Total cell extracts were analyzed with antibodies to procaspase 3, to PARP and
to GAPDH used as a protein loading control. (B) Quantitative analysis of PARP cleavage of three independent Western blot experiments. The data are shown as the mean ± SD
of cleaved PARP normalized to the uncleaved PARP. (C) SaOS-2/EV (lane 1) or SaOS-2/Caprin-1 (lane 2) cells or (D) U2OS/EV (lane 1) or U2OS/Caprin-1 (lane 2) cells were either
treated with the vehicle DMSO alone as a control, or with 3.5 μg/ml cisplatin, or pre-treated for 2 h with 100 μM of the general caspase inhibitor Z-VAD-FMK prior to cisplatin treat-
ment. Cell lysates were then subjected to immunoblot analysis for procaspase-3, PARP and GAPDH (upper panels). A quantitative analysis of PARP cleavage is shown in the lower
panels. The results are shown as the mean ± SD of cleaved PARP normalized to the uncleaved PARP from four independent Western blot experiments, *p b 0.05, **p b 0.01,
***p b 0.001.
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sion of Caprin-1 in tumor tissue had a shorter overall survival of
128 ± 12 months (mean ± SE) than 16 patients with non-detectable
Caprin-1 expression (mean overall survival of 173 ± 18 months).
However, the difference in overall survival was not statistically signiﬁ-
cant (p = 0.2056) (Fig. 7B). A second Kaplan–Meier survival analysis
that, in addition to Caprin-1 expression, distinguished between
patients with local or with metastatic disease revealed the shortest
survival time of 53 ± 12 months for 16 patients with metastases and
positive expression of Caprin-1 (Fig. 7C). Interestingly, 6 patients
with metastatic disease, but non-detectable Caprin-1 expression, sur-
vived considerably longer (mean survival time of 116 ± 32 months),but the overall survival was again not signiﬁcantly different from that
of the patients with Caprin-1 expressing tumors (p = 0.124). Thus, de-
spite the relatively small number of patients examined, our ﬁndings
implicate that Caprin-1 might be associated with worse outcome of
OS patients. Strikingly, a Kaplan–Meier survival analysis combining
robust expression of both Caprin-1 and Cyr61 demonstrated that
the overall survival of the patients with Caprin-1 and Cyr61
co-expressing tumors was signiﬁcantly (p b 0.05) shorter than that of
patients who expressed in their tumors one or the other or none of
the two proteins (Fig. 7D). Taken together, abundant expression of
Caprin-1 in primary tumors of OS patients might at least in part con-
tribute to its malignancy.
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Fig. 4. Overexpression of Caprin-1 in OS cells activates Akt and ERK1/2. Representative Western blot of extracts of SaOS-2/EV (lane 1), SaOS-2/Caprin-1 (lane 2), U2OS/EV (lane 3)
and U2OS/Caprin-1 (lane 4) OS cells, analyzed with antibodies to phospho-Ser473-Akt (p-Akt) and Akt (A), or with antibodies to phospho-ERK1/2 (p-ERK1/2), ERK1/2, and GAPDH
(B) indicating constitutive phosphorylation of Akt and ERK1/2 in Caprin-1 overexpressing cells. Respective quantitative analysis of Western blots is indicated in the right panels.
Bars are mean ± SD of p-Akt and p-ERK1/2 normalized to total Akt and total ERK1/2 respectively in individual protein extracts from three independent experiments, *p b 0.05,
**p b 0.01.
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Recent studies identiﬁed Cyr61 as a novel malignancy-enhancing
molecule in experimental OS in mice and as an immunohistochemical
marker in human OS tissue with prognostic potential for poor prog-
nosis [6,7]. In the present study, we undertook a proteomic approach,A 21 d 28 d
EV
*
Ca
pr
in
-1
21 d 28 d
B
Fig. 5. Overexpression of Caprin-1 in SaOS-2 OS cells promotes intratibial primary tumor g
tumor-bearing hind limbs of mice injected with SaOS-2/EV cells (EV, top panels) or with SaO
ance on indicated days after tumor cell injection. † = all mice injected with SaOS-2/Capri
growth over time in mice injected with SaOS2/EV cells (blue) or with SaOS-2/Caprin-1 cells
overall survival of mice injected with SaOS-2/Caprin-1 cells (red) compared to animals wi
imposed by the local ethical authorities, we injected SaOS-2/Caprin-1 and SaOS-2/EV cells
use the SaOS-2/EV injected mice as a control for both Cyr61 and Caprin-1 experiments.e.g. immunoprecipitation of Cyr61 combined with mass spectrome-
try, to identify proteins that, through interaction with Cyr61, may
co-operate with the malignancy-promoting protein during tumor de-
velopment and metastasis in OS. We identiﬁed Caprin-1 as a novel
Cyr61-interacting protein and demonstrated that Caprin-1, similar
to Cyr61 [7], has malignancy promoting properties in experimental35 d 90 d64 d
35 d
C
rowth and consequently shortens animal survival. (A) Representative X-ray images of
S-2/Caprin-1 cells (Caprin-1, bottom panels). The images show primary tumor appear-
n-1 cells had to be sacriﬁced before the indicated days. (B) Intratibial primary tumor
(red). (C) Kaplan–Meier survival analysis indicating signiﬁcantly (p b 0.0018) shorter
th SaOS2/EV cell-derived tumors (blue). *: Due to restrictions for animal experiments
in SCID mice at the same time as we injected SaOS-2/Cyr61 cells [7], allowing us to
AB
a b c d
SaOS-2/EV SaOS-2/Caprin-1
SaOS-2/EV SaOS-2/Caprin-1
Pr
im
ar
y 
tu
m
or
Lu
ng
s
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metastatic human SaOS-2 OS cell line.
First, we conﬁrmed the Cyr61/Caprin-1 interaction in intact cells
and investigated cellular responses to Caprin-1 overexpression in
vitro. In an effort to ﬁnd subcellular structures and locations where
Cyr61 and Caprin-1 interact, confocal imaging revealed predominant
co-localization of Cyr61 and Caprin-1 in SG, identiﬁed by TIA1 stain-
ing, a speciﬁc marker for these cellular structures. Interestingly, SG
formation in response to the overexpression of Caprin-1 has been
reported [17,26] and selective binding of Caprin-1 to mRNA encoding
c-Myc and cyclin D2 in SG was observed [17]. SG are multi-molecular
aggregates of stalled translation pre-initiation complexes that
prevent the accumulation of misfolded proteins [27]. SG and their
components have been implicated in the pathogenesis of several dis-
eases including cancer [24,28]. SG arise in response to cell stress and
are considered as subcellular structures that are involved in cell death
protective processes. This was proposed based on the observation
that stress-exposed cells with impaired SG assembly showed poorsurvival [29–31]. In cells with irreversible damage caused by stress,
however, SG appeared to direct these cells to apoptosis [24,32].
Along these lines, SG were shown to also contain apoptosis regulatory
factors in addition to RNA–protein complexes [24,32].
These previously reported ﬁndings together with our new results
describing a diminished cisplatin-provoked apoptotic response of
cells overexpressing Caprin-1 compared to control cells, point to a
hitherto unknown apoptosis-protective function of Caprin-1. It is
conceivable that the co-accumulation of Caprin-1 and Cyr61 in SG
reﬂects one apoptosis-protective activity of Caprin-1. Among other
cellular roles, Cyr61 is known to have apoptosis and senescence pro-
moting functions through interaction with integrin α6β1 and heparan
sulfate proteoglycans [33]. Thus, it is tempting to speculate that
Caprin-1, reported to be a component of SG, may sequester some pro-
teins, including Cyr61, to SG and thereby transiently neutralize their
activity. A similar mechanism of protein-inactivation by subcellular
granular deposition has been reported for TNF-α receptor associated
factor 2 (TRAF2). TRAF2 is sequestered by eIF4GI into heat shock-
p<0.05
C D
A B
Fig. 7. Kaplan–Meier analysis correlating immunohistochemical staining of Caprin-1 in human OS tissues in a tissue microarray with overall survival of the patients. (A) Representative
images of tumor tissue microarray sections showing entire spots (upper panels) and higher magniﬁcation (lower panel) with non-detectable (left), moderate (middle) and intense
(right) Caprin-1 immunostaining. (B) Overall survival of OS patients with non-detectable (Caprin-1 neg) or detectable (Caprin-1 pos) immunostaining of tumor tissue. (C) Overall
survival of patients without (Mets neg) or with (Mets pos) metastases and Caprin-1 neg or Caprin-1 pos tumors. (D) Overall survival of patients with tumors expressing both
Caprin-1 and Cyr61 (Caprin-1 & Cyr 61 pos) compared to the survival of all other patients.
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is a key transcriptional regulator of inﬂammatory responses and apo-
ptosis [34].
Gene-targeting experiments, using homologous recombination to
disrupt caprin-1 alleles, showed that Caprin-1 is needed for normal
progression through the G1-S phase of the cell cycle [15], but the cor-
responding molecular mechanisms employed by Caprin-1 are largely
unknown. Down-regulation of Caprin-1 by miR-16 has been consid-
ered as a mechanism that may contribute to the prolongation of the
G1 phase of the cell cycle [20]. The present study, on the other hand,
provides evidence for a regulatory function of Caprin-1 in Akt and
ERK1/2 phosphorylation, known to mediate signals that regulate
multiple cellular processes including cell proliferation. Interestingly,
overexpression of Caprin-1 in two OS cell lines led to elevated levels
of phosphorylated Akt and ERK1/2 consistent with a constitutive acti-
vation of both signaling. Surprisingly, however, proliferation rates of
Caprin-1-overexpressing and of control SaOS-2/EV cells in vitro
were not signiﬁcantly different (not shown).
Despite these observations in vitro, constitutively elevated levels
of phospho-Akt and -ERK1/2 in Caprin-1 overexpressing OS cells
might enhance their aggressiveness in vivo. This hypothesis was con-
ﬁrmed by the results of our study in the intratibial xenograft OS
model in SCID mice, in which SaOS-2/Caprin-1 cells showed a strik-
ingly enhanced malignant phenotype compared to control SaOS-2/
EV cells. This was reﬂected by a remarkably faster growth of the pri-
mary intratibial tumors and of the metastatic lesions in the lungs and,
consequently, by a signiﬁcantly shorter survival of the mice injected
with SaOS-2/Caprin-1 cells compared to the animals that received
control SaOS-2/EV cells. Although the indistinguishable proliferation
rates of the SaOS-2/Caprin-1 and of the SaOS-2/EV cells in vitro re-
main unexplained, the results of the animal studies are consistent
with a growth promoting effect of Caprin-1 overexpression in
SaOS-2 cells in both the bone and lung tissue environment, likelymediated by the activation of Akt and ERK1/2 pathways. The compar-
ative histological analysis of the lungs of mice injected with SaOS-2/
Caprin-1 cells and of animals injected with SaOS-2/EV cells suggested
that the observed massive increase in lung metastatic load upon
Caprin-1 overexpression was mainly caused by a faster and more in-
vasive growth of the cells in lung tissue rather than by an increase in
the number of cells metastasizing from the primary tumors. These
observations are different from our ﬁndings in mice with Cyr61
overexpressing SaOS-2 cell-derived intratibial tumors and lung me-
tastases [7]. These mice showed not only larger lung lesions, but
also a signiﬁcantly higher density of lung metastases than mice bear-
ing SaOS-2/EV cell-derived primary tumors. Thus, SaOS-2/Caprin-1
and SaOS-2/Cyr61 cells exhibit a slightly different phenotype when
developing to metastatic lesions in the lungs of SCID mice, but both
proteins enhanced the aggressiveness of SaOS-2 cells. Strikingly, a
Kaplan–Meier survival analysis correlating Caprin-1 and Cyr61 immu-
nostaining of OS tissues with the survival of the patients, showed that
Caprin-1/Cyr61 co-expression was associated with signiﬁcantly worse
survival of these patients compared to the patients with tumors that
expressed only one or none of the two proteins. These results are in
good agreement with our ﬁndings in the experimental OS model in
SCID mice and suggest indeed an in vivo cooperation between
Caprin-1 and Cyr61 that enhances OSmalignancy. Collectively, the pro-
posed apoptosis-protective activities of Caprin-1 overexpression to-
gether with the constitutive activation of Akt and ERK1/2 signaling
are consistent with the observed malignancy-promoting properties of
Caprin-1 protein in SaOS-2 OS cells in vivo.
5. Conclusion
This study identiﬁes Caprin-1 as a novel Cyr61-interacting protein
and elucidates a novel function of Caprin-1. Forced expression of
Caprin-1 in the human SaOS-2 and U2OS OS cell lines provoked
1182 A.A. Sabile et al. / Biochimica et Biophysica Acta 1832 (2013) 1173–1182co-accumulation with Cyr61 in stress granules, known to be involved
in apoptosis protective processes. Importantly, we found that SaOS-2
and U2OS cells overexpressing Caprin-1 are more resistant to
cisplatin-induced apoptosis. Furthermore, Caprin-1 overexpression
constitutively activated Akt and ERK1/2 signaling in both OS cell
lines. These observations at the cellular level are consistent with the
strikingly enhanced malignant phenotype of SaOS-2 OS cells over-
expressing Caprin-1 compared to control cells in an orthotopic OS
mouse model. Finally, our immunostaining analysis of Caprin-1/
Cyr61 co-expression in human OS tissues suggests an in vivo cooper-
ation between Caprin-1 and Cyr61. From this and previous studies,
which focused on Cyr61 [6,7], we conclude that both Caprin-1 and
Cyr61, at elevated expression levels in human OS, have related and
additive, but distinct OS malignancy-enhancing properties in addition
to largely unknown interaction-dependent functions that are current-
ly under investigation.
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